Entries for the Scrip Awards are now open. Now in their 20th year, the Awards seek to reward the outstanding achievements of the pharmaceutical, biotech and allied industries in improving human health.
Entries are now open for the 20th Annual Scrip Awards.
Firmly established as best-in-class for pharma and biotech, the Scrip Awards will be held on Wednesday, 4 December 2024 at...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.
The Belgian drugmaker is boosting its biologics capacity over the pond.
Sun’s founder hands top job to company longtimer Kirti Ganorkar as the firm implements a “structured and forward-looking” succession plan, while Richard Ascroft will lead the Indian drugmaker’s North America business.
The Belgian drugmaker is boosting its biologics capacity over the pond.
After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.
